A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676

Trial Details

NCT ID
NCT05780034
Phase
PHASE1
Sponsor
Accutar Biotechnology Inc
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • AC676
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Adult male and female patients, at least 18 years-of-age at the time of signature of the informed consent form (ICF).
  • Patients with histologically confirmed relapsed/refractory Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lympho…
  • Must have received at least 2 prior systemic therapies or have no other therapies to provide significant clinical benefit in the opinion of the Inv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →